The aim of this study was to test the hypothesis that inhibiting mammalian target of rapamycin and insulin-like growth factor-1 receptor would be efficacious in metastatic uveal melanoma. This was a phase 2 trial of everolimus 10 mg daily plus pasireotide long-acting release 60 mg every 28 days enrolling patients with progressive, metastatic uveal melanoma to treatment until progression by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) or unacceptable toxicity. The primary endpoint was clinical benefit rate, defined as any objective response or RECIST 1.1 stable disease at 16 weeks. A subset of patients underwent baseline indium-111-octreotide scans.
A total of 14 patients were enrolled, of which 13 were evaluable for the primary endpoint, before the study was terminated due to poor accrual. Three of 13 (26%) patients obtained clinical benefit. Seven of 13 (54%) had stable disease lasting for a median of 8 weeks (range: 8-16 weeks). Grade 3 adverse events deemed at least possibly related to study drugs were hyperglycemia (n = 7), oral mucositis (n = 2), diarrhea (n = 1), hypophosphatemia (n = 1), and anemia (n = 1). Seven of 14 (50%) patients required at least one dose reduction due to toxicity. Seven of eight (88%) patients with baseline indium-111-octreotide scans had at least one avid lesion, with significant intrapatient heterogeneity. There was a trend toward an association between octreotide avidity and cytostatic response to therapy (P = 0.078). 
Background
Uveal melanoma is the most common primary intraocular malignancy in adults, with an incidence of 4-5 cases per million [1] . Approximately half of all patients with uveal melanoma will eventually develop metastatic disease, and their prognosis remains poor [2] . Over the past several years, studies have identified activating mutations in the Gα protein subunits GNAQ and GNA11 in the vast majority of uveal melanomas that lead to downstream activation of multiple signaling pathways, including mitogen-activated protein kinase (MAPK), protein kinase C (PKC), and phosphoinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) [3] [4] [5] [6] . Recently, a randomized phase 2 trial of the mitogen-activated protein/extracellular signalrelated kinase kinase (MEK) inhibitor selumetinib demonstrated a progression-free survival (PFS) benefit versus the investigator's choice of chemotherapy (median: 16 vs. 8 weeks) [7] . This has provided the proof of concept that targeted inhibition of growth signals in uveal melanoma can lead to clinical benefit. Recently, a phase 3 trial of dacarbazine versus dacarbazine plus selumetinib failed to demonstrate an improvement in PFS, suggesting combined inhibition of multiple signaling pathways may be required for sustained clinical benefit. PI3K/Akt/mTOR signaling is dysregulated in a variety of human cancers [8] . In uveal melanoma, 60% of metastatic tumors display loss of phosphatase and tensin homolog (PTEN), a tumor suppressor that inhibits this pathway [9] . As a result, mTOR represents an attractive therapeutic target in uveal melanomas. Clinical resistance to mTOR monotherapy is a frequent occurrence, however, and combination therapeutic strategies may be required for sustained clinical benefit. One potential mechanism of resistance to mTOR inhibition is rebound activation of insulin-like growth factor-1 receptor (IGF1R) pathway signaling [10] . In uveal melanoma, tumor IGF1R expression has been associated with disease progression, and in-vitro inhibition of IGF1R causes uveal melanoma tumor regression [11, 12] .
Insulin-like growth factor-1 (IGF1) ligand levels in plasma are increased by somatostatin signaling, and in one study of 25 uveal melanoma specimens, 100% expressed somatostatin receptor (SSTR)-2A, 56% expressed SSTR-5, and 28% expressed SSTR-3 [13] . This suggests that nuclear imaging with an octreotide analog such as indium-111 ( 111 In)-octreotide (octreoscan) that binds to SSTR-2A may be used to select for patients with advanced uveal melanoma that may be more likely to respond to IGF1R pathway inhibition. A recent report by Valsecchi et al. [14] demonstrated 111 In-octreotide avidity in 14 of 30 (44%) patients with advanced uveal melanoma. In their cohort, seven patients with positive 111
In-octreotide scans received Sandostatin (Novartis Pharma AG, Basel, Switzerland) long-acting release (LAR) outside of a formal clinical trial, and two patients had clinically stable disease for over 5 months [14] .
Combination IGF1R and mTOR inhibition, therefore, may provide clinical benefit in uveal melanoma. To investigate this, we launched a single-arm phase 2 trial of combined mTOR and IGF1R inhibition with everolimus and pasireotide LAR in patients with metastatic uveal melanoma. Correlative analysis was performed by measuring plasma levels of IGF1 and baseline
111
In-octreotide scans. We hypothesized that plasma IGF1 levels would decrease while receiving pasireotide LAR, consistent with IGF1R pathway inhibition, and patients with positive In-octreotide uptake in their tumors would derive more benefit from the study combination than those whose tumors did not take up 111
In-octreotide.
Patients and methods

Trial design
This is an open-label, single-arm phase 2 trial in which patients with metastatic uveal melanoma received everolimus (RAD001) 10 mg orally daily plus pasireotide LAR (SOM230) 60 mg intramuscularly once every 28 days until progression by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1) or unacceptable toxicity. Up to two dose reductions for both everolimus and pasireotide LAR were allowed to accommodate for toxicities. This protocol (NCT01252251) was approved by the Memorial Sloan Kettering Cancer Center Institutional Review Board.
Key inclusion criteria were age more than 18 years, histologically confirmed metastatic uveal melanoma with measurable disease per RECIST 1.1, progression on prior therapy in the opinion of the treating physician, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, and adequate end-organ function. Key exclusion criteria included brain metastases with stability of less than 2 months, prior therapy with an mTOR inhibitor, or uncontrolled hyperglycemia or hypertriglyceridemia. Patients were evaluated through cross-sectional imaging at baseline and then every 8 weeks, corresponding to the end of even numbered cycles. Adverse events (AEs) were coded using Common Terminology Criteria for Adverse Events version 4.0.
The primary endpoint was clinical benefit rate (CBR), defined as RECIST 1.1 stable disease at 16 weeks or any objective response. Secondary endpoints included PFS and overall survival. Patients who did not complete one cycle (28 days) due to toxicity were considered replaceable for purposes of the primary endpoint.
Imaging and plasma correlates
Optional 111
In-octreotide scans were performed before starting therapy using planar imaging done at 4 and 24 h postinjection of radiotracer. Single-photon emission computed tomography (SPECT) or SPECT/computed tomography (CT) of the abdomen was performed at 4 h postinjection, and SPECT or SPECT/CT of the chest at 24 h postinjection. All scans were retrospectively reviewed by a board-certified nuclear medicine physician on a Hermes Workstation (Hermes Medical Solutions, Stockholm, Sweden). A 1-cm three-dimensional spherical region of interest was placed over all malignant lesions noted by the study radiologist, and threedimensional maximum and mean counts were recorded. Maximum and mean counts from normal liver and aortic arch (for blood pool) were recorded to serve as reference regions. Mean background counts were used in determining tumorto-liver and tumor-to-blood pool ratios. Ratios of uptake in lesions versus background were used to derive semiquantitative assessment of uptake intensity, and any lesion with a ratio of more than 2 above background aortic arch uptake at either 4 or 24 h was considered avid. Serum IGF1 levels were assayed at baseline and after every 4 weeks using a commercial liquid chromatographymass spectrometry assay (Quest Diagnostics, San Juan Capistrano, California, USA) to assess changes in the IGF1R signaling axis.
Statistical methods
A Simon two-stage design was utilized to evaluate the CBR. To evaluate a promising CBR of 30% versus nonpromising CBR of 10% with 90% power at an α of 0.10, at least five of 25 total patients would have to achieve clinical benefit. The trial was designed to terminate for futility if only one or none of the first 16 patients achieved clinical benefit.
To explore the association between study drug response and 111
In-octreotide avidity, each RECIST 1.1 target lesion was assessed from baseline to first follow-up CT scan and classified as an 111 In-octreotide avid or nonavid lesion. As multiple lesions were measured within each patient, a generalized estimating equation model was utilized to assess association between 111 In-octreotide avidity of the lesion and percentage changes in size by RECIST. P values of less than 0.05 were considered significant.
Results
Demographics
Between 1 January 2011 and 31 April 2014, 21 patients consented, of whom 14 enrolled in study. The clinical characteristics of these 14 patients are listed in Table 1 . Median age was 61 years (range: 41-83 years). Median ECOG performance status was 0 (range: 0-1). The majority of patients had M1b or M1c disease (64 and 14%, respectively) by American Joint Committee on Cancer 7th edition staging guidelines for uveal melanoma [15] . Median number of prior systemic therapy was 2 (range: 1-5), with nine of 14 (64%) having progressed on a prior MEK inhibitor. Six patients also received at least one prior locoregional therapy. GNAQ/GNA11 exon 5 mutational status was assessed in 12 of 14 patients. Ten of these 12 patients had Q209 mutations (GNAQ: n = 5, GNA11: n = 5). Of the two exon 5 wild-type samples, one had a GNA11 exon 4 R183Q mutation and one was not tested further.
Efficacy
The study was terminated early because of poor accrual. Thirteen of 14 patients were evaluable for the primary endpoint; one patient withdrew consent within 1 week on the study. Please see Table 2 for the efficacy for each patient on the study. Three of 13 (23%) patients had stable disease (SD) for at least 16 weeks and were considered to have derived clinical benefit. Overall, SD was the best objective outcome in seven of 13 patients. Median duration of SD in these patients was 8 weeks (range: 8-16 weeks). Six of 13 patients had progressive disease on first assessment. Two patients had disease regression (− 10 and − 28%), and both had tumors that were wild type for GNAQ/GNA11 exon 5 mutations. Median time on treatment was 8 weeks (range: 1-23 weeks) (Fig. 1) . Reasons for stopping therapy were disease progression (n = 9), toxicity (n = 3), or a switch to attempt a newly available alternate therapy (n = 2). Median PFS from first date of treatment for the 13 evaluable patients was 16 weeks (range: 7-23 weeks) (Fig. 2) . Median overall survival from first day of study treatment was 11 months (range: 4.5-28.5 months) (Fig. 3 ). Table 3 depicts all AEs occurring in more than one patient and grade 3 AEs occurring in one or more patient deemed at least possibly related to study drugs. All 14 patients experienced at least one possibly related AE. The most frequently identified AEs were metabolic (hyperglycemia, hypertriglyceridemia, hypercholesterolemia), gastrointestinal (diarrhea, oral mucositis), or hematologic (leukopenia, thrombocytopenia, neutropenia) in nature. The grade 3 AEs deemed at least possibly related were hyperglycemia (n = 7), oral mucositis (n = 2), diarrhea (n = 1), hypophosphatemia (n = 1), and anemia (n = 1). There were no grade 4 or 5 AEs.
Toxicity
Seven of 14 (50%) patients had at least one dose reduction of everolimus. The reasons for dose reduction were mucositis (n = 6) and anemia (n = 1). Three patients discontinued study treatment due to toxicity: two for grade 2 mucositis and one for grade 3 diarrhea.
Indium-111-octreotide scans, plasma insulin-like growth factor-1 receptor levels, and outcomes Eight patients who were evaluable for response underwent baseline 111 In-octreotide scans, of which seven of eight (88%) had positive uptake in one or more metastatic lesion. There was heterogeneous uptake in most patients (Table 2 and Fig. 4) . Five of seven patients with more than one assessable lesion had both 111 In-octreotide avid and nonavid tumors. Overall, 14 of 28 (50%) lesions were 111 In-octreotide avid. Among the 26 lesions that had been labeled prospectively as RECIST 1.1 target lesions, 12 were avid. There was a trend toward 111 In avidity and lower percent growth in lesion size on therapy that did not meet statistical significance (P = 0.078). High  0  3  Yes  1  GNAQ  Q209L  2  Male  66  M1b  M1c  High  0  2  Yes  1  GNAQ  Q209P  3  Male  55  M1b  M1c  Normal  0  2  Yes  0  GNAQ  Q209L  4  Female 63  M1b  M1c  Normal  0  2  Yes  0  GNA11  Q209L  5  Male  61  M1b  M1c  Normal  1  2  Yes  0  GNA11  Q209L  6  Female 52  M1a  M1b  Normal  0  1  Yes  0  GNAQ  Q209L  7  Female 72  M1c  M1c  High  0  2  Yes  0  Not done  Not done  8  Female 42  M1b  M1c  High  0  1  No  1  Unknown  Ex5 wt  9  Female 72  M1b  M1c  High  0  1  Yes  0  GNA11  Q209L  10  Female 74  M1a  M1c  High  0  5  Yes  0  GNA11  R183Q  11  Female 60  M1a  M1c  High  1  4  No  5  GNA11  Q209L  12  Male  56  M1b  M1c  High  0  3  No  0  GNA11  Q209L  13  Male  83  M1b  M1c  High  0  1  No  1  Not done  Not done  14  Male  58  M1c  M1c  High  0  3  No  3  GNAQ  Q209R a High refers to a value above the upper limit of normal. ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MEK, mitogen-activated protein/extracellular signal-related kinase kinase.
In the 13 evaluable patients, plasma IGF1 levels after one cycle of therapy were decreased a median of 54% compared with baseline (range: 7-75%), which was statistically significant (P < 0.001, paired t-test). This reduction in IGF1 levels was sustained for patients who 
Duration of therapy
Swim plot of treatment duration on study and reasons for discontinuation. Three patients obtained more than 16 weeks of clinical benefit. Patients came off for either progression of disease ( ; n = 9), toxicity ( ; n = 3), or pursuing immune-based therapy ( ; n = 2). All AEs occurring in more than patient regardless of severity or any grade 3 or higher AEs at least possibly related to study drugs are depicted. There were no grade 4 or 5 toxicities related to study drugs. AE, adverse event; CPK, creatinine phosphokinase.
mTOR + IGF1R blockade in uveal melanoma Shoushtari et al. 275 remained on therapy (data not shown). There was no association between IGF1 plasma levels and clinical benefit.
Discussion
Metastatic uveal melanoma remains a disease with poor prognosis, with most patients surviving 6-12 months following diagnosis of metastasis [16, 17] . Multiple ongoing clinical trials are investigating the clinical benefit of inhibiting MEK, PKC, and/or PI3K, and there is a critical need to identify relevant therapeutic targets in this disease [18] .
In this highly pretreated cohort of patients with metastatic uveal melanoma, there was preliminary evidence of clinical benefit with combined IGF1R and mTOR inhibition. Although the trial did not complete accrual, the fact that three patients obtained more than 16 weeks of stable disease suggests certain patients with advanced uveal melanoma may benefit from this therapy. Interestingly, all three of these patients had previously progressed on MEK inhibitors (selumetinib, n = 2; trametinib, n =1). Recent work has identified that Akt upregulation is common in MEK-resistant cell lines and showed Harvey rat sarcoma viral oncogene homolog signaling is an important upstream mediator [19] . The possibility that mTOR and/or IGF1 signaling plays some additional role in progression to MEK inhibitors requires further investigation. There were no ontreatment biopsies to assess the pharmacodynamic effect of everolimus in this study. The decrease in serum IGF1 levels, however, suggests pasireotide LAR inhibited signaling of the IGF1 axis to varying extents.
Of the eight evaluable patients with an 111 In-octreotide scan, seven (88%) had at least one octreotide-avid metastasis. This rate is somewhat higher than the 44% rate described by Valsecchi et al. [14] despite using the same cutoff for positivity of two-fold increase above background. Our study is the first, to our knowledge, to describe intrapatient heterogeneity in 111 In-octreotide avidity between multiple tumors and suggests there is intrapatient heterogeneity in tumor expression of SSTR-2A. In this small sample size, there was a trend between 111 In-octreotide avidity and stability of disease with combined anti-IGF1R plus mTOR therapy that did not reach statistical significance. This suggests that, while the routine use of 111 In-octreotide scans in this disease cannot be recommended to document extent of metastatic disease, there may be a biologically relevant relationship between 111 In-octreotide avidity and cytostatic effect of somatostatin analogues in uveal melanoma. This should be investigated in a larger cohort of patients, potentially utilizing more sensitive nuclear imaging modalities such as gallium-68-octreotate PET [20] .
As our understanding of uveal melanoma biology increases and more clinical trials utilize targeted inhibitors of growth signals, it will become increasingly important to identify rational strategies to combine antineoplastic agents. This study is the first to our knowledge to combine targeted inhibition in uveal melanoma. Combination therapy with mTOR and IGF1R inhibitors led to a relatively high rate of AEs, most commonly metabolic, gastrointestinal, and hematologic in nature. Dose reductions, largely for mucositis, may have limited the long-term tolerability of this combination and slowed accrual of this trial. Nonetheless, given the presence of prolonged stable disease in select patients refractory to multiple therapies, future trials investigating the role of mTOR and/or IGF1R inhibition in uveal melanoma are warranted.
